Myalept approved for rare fat tissue disorder

(HealthDay)—Myalept (metreleptin for injection) has been approved by the U.S. Food and Drug Administration to treat complications of leptin deficiency for people with the congenital or acquired generalized forms of lipodystrophy.

The disorder is associated with a lack of fat tissue. Leptin, produced by , is a hormone that helps regulate food intake and other hormones such as insulin, the FDA said Tuesday in a news release.

People with lipodystrophy are at greater-than-average risk of developing serious at a young age, making them more prone to out-of-control diabetes and high levels of blood fats called triglycerides.

Myalept was evaluated in a clinical study of 48 people with generalized lipodystrophy and its complications. The trial showed good results in and reduced blood triglycerides, the FDA said.

People taking Myalept may develop a resistance to the drug, making it less effective over time and increasing their risk of severe infection, the agency said.

Less serious side effects could include , headache, weight loss and abdominal pain. The drug is not recommended for people with general obesity.

The FDA said it has ordered a number of post-marketing studies to further evaluate the drug and its potential to cause serious side effects.

Myalept is marketed by Amylin Pharmaceuticals, based in San Diego.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Blood sugar monitoring system approved for children

Feb 04, 2014

(HealthDay)—U.S. Food and Drug Administration approval of the Dexcom G4 Platinum Continuous Monitoring System has been expanded to include children with diabetes aged 2 years to 17 years, the agency said.

Vimizim approved for rare childhood disorder

Feb 17, 2014

(HealthDay)—Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.

Tretten approved for genetic clotting disorder

Dec 23, 2013

(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.

Northera approved for rare blood pressure condition

Feb 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Stent to treat pancreatic cysts approved

Dec 19, 2013

(HealthDay)—The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments